scholarly journals How can traditional Chinese medicine contribute to the therapeutic approach in coronavirus disease 2019 (COVID-19)? A review of the registered clinical trials

2020 ◽  
Author(s):  
Hui Luo ◽  
Ming Yang ◽  
Qiao-ling Tang ◽  
Xiao-yang Hu ◽  
Merlin L. Willcox ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Tai Chi ◽  
Relevant Information ◽  
Current Status ◽  
Therapeutic Effects ◽  
Global Management ◽  
Chinese Herbal ◽  
Chinese Patent

Abstract Background: Since the outbreak of coronavirus disease 2019 (COVID-19) in January 2020, Traditional Chinese Medicine (TCM) has been fully and deeply involved in the treatment of COVID-19 in China. An increasing number of clinical trials has been registered to evaluate the effects of TCM in the prevention and therapeutic management of COVID-19.Objective: This study aims to review the existing TCM registered trials, identify promising and available TCM therapies, in order to provide reference for the global management of COVID-19. Methods: All clinical trials on TCM for COVID-19 registered in eight registry platforms worldwide were searched up to May 14, 2020. The data of registration trend, design, objective, interventions, current status, and relevant information were reviewed and summarized. Supportive information on the progress, results and potential value of the included registered trials were searched and reviewed from databases and official websites. Results: 161 TCM trials registered in three registries from January 26 to May 14 were included. 94 (58.4%) were randomized controlled trials, followed by controlled clinical trials (25, 15.5%), single-arm clinical studies (18, 11.2%) and others (24, 14.9%). 114 trials (70.8%) assessed therapeutic effects; while the remaining were for prevention, rehabilitation, and TCM syndrome epidemiology. The three most evaluated TCM interventions were Chinese herbal medicine (CHM) in the preparation forms of formulae decoction/granule (41.7%), Chinese patent medicine (24.8%) and Chinese herbal-derived injections (8.1%). The common outcomes in therapeutic trials were symptoms and signs (65.8%), time to viral clearance on PCR (50.9%), and improvement in CT images (43.9%). 78 trials (48.4%) had started recruiting and six trials (3.7%) had completed recruiting. Among the TCM interventions identified from the registered trials, the following are worthy of attention and may have the potential feasibility of being evaluated and then used worldwide due to their rigorous design, previous evidence and availability: for prevention in high-risk populations or suspected cases, moxibustion, Huoxiang Zhengqi pill and Jinye Baidu granule could be considered; for treatment, Qingfei Paidu decoction or granules in mild, moderate and severe cases, Huashi Baidu decoction, Lianhua Qingwen caplsule, Toujie Quwen granule and Xiyanping injection in mild and moderate cases, and Xuebijing injection in severe cases could be considered. For rehabilitation of cured patients, the effect of Tai Chi and Liuzijue on the patients’ lung function and quality of life deserves attention.Conclusion: A series of promising potentially effective TCM interventions including CHM formulae, Chinese patent medicines, herbal-derived injections and non-drug therapies have been identified in clinical practice and are being evaluated by registered clinical trials. Available and applicable interventions within relevant trials are worthy of worldwide attention and application, in order to contribute to the global management of COVID-19 epidemic.

scholarly journals Therapeutic Effects and Molecular Mechanisms of Bioactive Compounds Against Respiratory Diseases: Traditional Chinese Medicine Theory and High-Frequency Use

2021 ◽  
Vol 12 ◽  
Author(s):  
Jing Wang ◽  
Qibiao Wu ◽  
Lu Ding ◽  
Siyu Song ◽  
Yaxin Li ◽  
...  
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Clinical Application ◽  
Bioactive Compounds ◽  
High Frequency ◽  
Lung Diseases ◽  
Respiratory Diseases ◽  
Molecular Mechanisms ◽  
Therapeutic Effects ◽  
Chinese Herbal

Respiratory diseases, especially the pandemic of respiratory infectious diseases and refractory chronic lung diseases, remain a key clinical issue and research hot spot due to their high prevalence rates and poor prognosis. In this review, we aimed to summarize the recent advances in the therapeutic effects and molecular mechanisms of key common bioactive compounds from Chinese herbal medicine. Based on the theories of traditional Chinese medicine related to lung diseases, we searched several electronic databases to determine the high-frequency Chinese medicines in clinical application. The active compounds and metabolites from the selected medicines were identified using the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) by analyzing oral bioavailability and drug similarity index. Then, the pharmacological effects and molecular mechanisms of the selected bioactive compounds in the viral and bacterial infections, inflammation, acute lung injury (ALI), chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, asthma, and lung cancer were summarized. We found that 31 bioactive compounds from the selected 10 common Chinese herbs, such as epigallocatechin-3-gallate (EGCG), kaempferol, isorhamnetin, quercetin, and β-sitosterol, can mainly regulate NF-κB, Nrf2/HO-1, NLRP3, TGF-β/Smad, MAPK, and PI3K/Akt/mTOR pathways to inhibit infection, inflammation, extracellular matrix deposition, and tumor growth in a series of lung-related diseases. This review provides novel perspectives on the preclinical study and clinical application of Chinese herbal medicines and their bioactive compounds against respiratory diseases.

scholarly journals Current Status and Evaluation of Randomized Clinical Trials of Traditional Chinese Medicine in the Treatment of Cardiovascular Diseases

2022 ◽  
Vol 2022 ◽  
pp. 1-13
Author(s):  
Xi Guo ◽  
Xiaojun Chen ◽  
Jinlan Chen ◽  
Zhiping Tan ◽  
Yifeng Yang ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Chinese Medicine ◽  
Cardiovascular Diseases ◽  
Traditional Chinese Medicine ◽  
Western Medicine ◽  
Randomized Clinical Trials ◽  
Treatment Guidelines ◽  
Current Status ◽  
Medicine Research ◽  
Randomized Controlled Clinical Trials

Traditional Chinese medicine has long been applied to various diseases in China for a few thousand years. In recent years, its market has gradually developed from Asian countries to Western countries. At present, due to the lack of evidence-based medicine research, the effect of traditional Chinese medicine on the prevention and treatment of cardiovascular disease remains unclear. In evaluating the efficacy and safety of drugs, randomized controlled clinical trials (RCTs) are recognized as the gold standard for testing the effectiveness and safety of treatments and could offer the best evidence for the formulation of clinical treatment guidelines. Although traditional Chinese medicine has long been used to treat cardiovascular diseases, the research on the application of RCT to test the combination of traditional Chinese and Western medicine therapy or single traditional Chinese medicine therapy started late, and the number is comparably small. In order to summarize and objectively evaluate the research results of integrated traditional Chinese and Western medicine in intervention of cardiovascular diseases, we reviewed the literature of RCTs in this field by searching some Chinese and English databases and put forward some suggestions for the future development and research of traditional Chinese medicine.

scholarly journals Calling for improved quality in the registration of traditional Chinese medicine during the public health emergency: a survey of trial registries for COVID-19, H1N1, and SARS

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Zhuoran Kuang ◽  
◽  
Xiaoyan Li ◽  
Jianxiong Cai ◽  
Yaolong Chen ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Secondary Outcome ◽  
Specific Information ◽  
Clinical Trial Registry ◽  
Data Set ◽  
Diagnosis Criteria

Abstract Objective To assess the registration quality of traditional Chinese medicine (TCM) clinical trials for COVID-19, H1N1, and SARS. Method We searched for clinical trial registrations of TCM in the WHO International Clinical Trials Registry Platform (ICTRP) and Chinese Clinical Trial Registry (ChiCTR) on April 30, 2020. The registration quality assessment is based on the WHO Trial Registration Data Set (Version 1.3.1) and extra items for TCM information, including TCM background, theoretical origin, specific diagnosis criteria, description of intervention, and outcomes. Results A total of 136 records were examined, including 129 severe acute respiratory syndrome coronavirus 2 (COVID-19) and 7 H1N1 influenza (H1N1) patients. The deficiencies in the registration of TCM clinical trials (CTs) mainly focus on a low percentage reporting detailed information about interventions (46.6%), primary outcome(s) (37.7%), and key secondary outcome(s) (18.4%) and a lack of summary result (0%). For the TCM items, none of the clinical trial registrations reported the TCM background and rationale; only 6.6% provided the TCM diagnosis criteria or a description of the TCM intervention; and 27.9% provided TCM outcome(s). Conclusion Overall, although the number of registrations of TCM CTs increased, the registration quality was low. The registration quality of TCM CTs should be improved by more detailed reporting of interventions and outcomes, TCM-specific information, and sharing of the result data.

scholarly journals Metabolomics study of the therapeutic mechanism of a Chinese herbal formula on collagen-induced arthritis mice

RSC Advances ◽  
2019 ◽  
Vol 9 (7) ◽  
pp. 3716-3725 ◽  
Author(s):  
Zhen Jin ◽  
Ji-da Zhang ◽  
Xin Wu ◽  
Gang Cao
Keyword(s):  
Rheumatoid Arthritis ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Herbal Formula ◽  
Collagen Induced Arthritis ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Therapeutic Mechanism ◽  
Metabolomics Study

Wenjinghuoluo (WJHL) prescription, the typical rheumatoid arthritis (RA) treatment compound in traditional Chinese medicine, shows favorable efficacy.

scholarly journals Therapeutic Effects of Traditional Chinese Medicine on Spinal Cord Injury: A Promising Supplementary Treatment in Future

2016 ◽  
Vol 2016 ◽  
pp. 1-18 ◽  
Author(s):  
Qian Zhang ◽  
Hao Yang ◽  
Jing An ◽  
Rui Zhang ◽  
Bo Chen ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Epigallocatechin Gallate ◽  
Therapeutic Effects ◽  
Cord Injury ◽  
Supplementary Treatment ◽  
Natural Drugs ◽  
Doctoral Dissertations

Objective. Spinal cord injury (SCI) is a devastating neurological disorder caused by trauma. Pathophysiological events occurring after SCI include acute, subacute, and chronic phases, while complex mechanisms are comprised. As an abundant source of natural drugs, Traditional Chinese Medicine (TCM) attracts much attention in SCI treatment recently. Hence, this review provides an overview of pathophysiology of SCI and TCM application in its therapy.Methods. Information was collected from articles published in peer-reviewed journals via electronic search (PubMed, SciFinder, Google Scholar, Web of Science, and CNKI), as well as from master’s dissertations, doctoral dissertations, and Chinese Pharmacopoeia.Results. Both active ingredients and herbs could exert prevention and treatment against SCI, which is linked to antioxidant, anti-inflammatory, neuroprotective, or antiapoptosis effects. The detailed information of six active natural ingredients (i.e., curcumin, resveratrol, epigallocatechin gallate, ligustrazine, quercitrin, and puerarin) and five commonly used herbs (i.e., Danshen, Ginkgo, Ginseng, Notoginseng, and Astragali Radix) was elucidated and summarized.Conclusions. As an important supplementary treatment, TCM may provide benefits in repair of injured spinal cord. With a general consensus that future clinical approaches will be diversified and a combination of multiple strategies, TCM is likely to attract greater attention in SCI treatment.

scholarly journals Clinical Therapeutic Effects of Aspirin in Combination with Fufang Danshen Diwan, a Traditional Chinese Medicine Formula, on Coronary Heart Disease: A Systematic Review and Meta-Analysis

2016 ◽  
Vol 39 (5) ◽  
pp. 1955-1963 ◽  
Author(s):  
Jianchun Huang ◽  
Xiaojun Tang ◽  
Fangxing Ye ◽  
Junhui He ◽  
Xiaolong Kong
Keyword(s):  
Systematic Review ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Aspirin Therapy ◽  
Therapeutic Effects ◽  
Chinese Medicine Formula

Background/Aims: Coronary heart disease is characterized by vascular stenosis or occlusion resulting in myocardial ischemia, hypoxia and necrosis. In China, the combination of aspirin and Fufang Danshen Diwan (FDD), a traditional Chinese medicine formula, has been suggested in the treatment of coronary heart disease. There have been several studies comparing the effectiveness of aspirin alone and in combination with FDD to treat coronary artery disease; however, it remains unclear whether combined aspirin therapy is superior. This study was thus designed to clarify this issue through a systematic review and meta-analysis. Methods: Databases including PubMed, EMBASE, China National Knowledge Infrastructure (CNKI) database, Wanfang Data and VIP Information were searched. Papers were reviewed systematically by two researchers and analyzed using Cochrane software Revman 5.1. Results: Fourteen randomized controlled trials enrolling 1367 subjects were included. Meta-analyses revealed that aspirin in combination with FDD was significantly more effective at alleviating angina pectoris and improving electrocardiogram (ECG) results relative to aspirin therapy alone, reflected by the summary effects for the clinical markedly effective (OR = 2.45; 95% CI 1.95-3.08) and the total effective (OR = 3.92; 95% CI 2.87-5.36) rates. In addition, combined aspirin and FDD was significantly more efficacious than aspirin monotherapy at improving blood lipid levels, as indicated by the following outcomes: 1) reduction of TC level (SMD −1.12; 95% CI −1.49 to −0.76); 2) reduction of TG level (SMD −0.94; 95% CI −1.15 to -0.74); 3) reduction of LDL level (SMD -0.68; 95% CI -0.88 to -0.48); and 4) improvement of HDL level (SMD 0.52; 95% CI 0.04 to 0.99 ). No serious adverse events were reported in any of the included trials. Conclusion: The present meta-analysis demonstrated that aspirin in combination with FDD was more effective than aspirin alone for treating coronary heart disease. More full-scale randomized clinical trials with reliable designs are recommended to further evaluate the clinical benefits and long-term effectiveness of FDD for the treatment of coronary heart disease.

scholarly journals Molecular Imaging in Traditional Chinese Medicine Therapy for Neurological Diseases

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Zefeng Wang ◽  
Haitong Wan ◽  
Jinhui Li ◽  
Hong Zhang ◽  
Mei Tian
Keyword(s):  
Chinese Medicine ◽  
Molecular Imaging ◽  
Traditional Chinese Medicine ◽  
Neurological Disorders ◽  
Neurological Diseases ◽  
Chinese Herb ◽  
Public Health Care ◽  
Therapeutic Effects ◽  
Cord Injury

With the speeding tendency of aging society, human neurological disorders have posed an ever increasing threat to public health care. Human neurological diseases include ischemic brain injury, Alzheimer’s disease, Parkinson’s disease, and spinal cord injury, which are induced by impairment or specific degeneration of different types of neurons in central nervous system. Currently, there are no more effective treatments against these diseases. Traditional Chinese medicine (TCM) is focused on, which can provide new strategies for the therapy in neurological disorders. TCM, including Chinese herb medicine, acupuncture, and other nonmedication therapies, has its unique therapies in treating neurological diseases. In order to improve the treatment of these disorders by optimizing strategies using TCM and evaluate the therapeutic effects, we have summarized molecular imaging, a new promising technology, to assess noninvasively disease specific in cellular and molecular levels of living models in vivo, that was applied in TCM therapy for neurological diseases. In this review, we mainly focus on applying diverse molecular imaging methodologies in different TCM therapies and monitoring neurological disease, and unveiling the mysteries of TCM.

Sign in / Sign up

Export Citation Format

Share Document